Blog
Is Intel Stock Finally Worth Buying?
The odds were stacked against Intel (NASDAQ: INTC) going into its second-quarter earnings report. The company still managed to put up a strong showing despite the competitive challenges it has been
Zoom Continues to Improve Its Platform
Zoom Video Communications (NASDAQ: ZM) has benefited from the wave of new users over the course of the pandemic, but the company is not resting on its laurels. This video platform has expanded its
2 Cannabis Stocks to Buy and Hold for 20 Years
If you want to invest in the red-hot cannabis industry to capture some of its formidable expected growth, you've probably already realized that there are a bunch of less-than-spectacular options out
Peloton Is 1 Stock That Can Buck Reopening Trends
The sales surge Peloton (NASDAQ: PTON) experienced during the pandemic was clearly beneficial for the company. With many gyms closed to help slow the spread of the virus, demand for home fitness
Nvidia and ARM Could Turn the Internet of Things Into the Internet of Everything
Nvidia (NASDAQ: NVDA) has been clear about why it wants to acquire top chip designer ARM Holdings from its current parent organization, Softbank Group. Nvidia has built itself into a tech powerhouse
Etsy Adds Some Fashion to Its E-Commerce Shopping Basket
At the beginning of June, Etsy (NASDAQ: ETSY) announced it was acquiring Depop, an online fashion reseller for $1.6 billion. Investors may be wondering what to make of this move and how this new
Are Johnson & Johnson's Legal Troubles Enough of a Reason to Avoid the Stock?
Johnson & Johnson (NYSE: JNJ) has been a profitable business to invest in over the years. But its legal concerns have been growing -- the company now faces tens of thousands of lawsuits relating to
Are Oil Stocks Undervalued?
There are two conflicting trends in the oil market right now when you look at the big picture and the near-term outlook. And whether there is value in oil stocks probably depends on your view of
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
Cassava Sciences (NASDAQ: SAVA) has been the ultimate zero-to-hero biotech stock. Over the past year, shares have gained a stunning 3,630%. The company went from a virtual nobody to an innovator
Is Aurora Cannabis a Buy?
Aurora Cannabis (NASDAQ: ACB) has long been an underperforming marijuana stock. And year to date, it's off to another rocky start, down 15% in 2021 while the Horizons Marijuana Life Sciences ETF has
3 Must-See Metrics Behind Facebook's Staggering Q2 Growth
Following a string of very strong reports from companies in the digital advertising space in the days leading to Facebook's (NASDAQ: FB) earnings release, expectations were high going into the
Is It Too Late to Buy Roku Stock?
Roku (NASDAQ: ROKU) has streamed massive profits for its investors since its debut as a public stock in September 2017. In just under four years, Roku's stock price has risen by more than 1,900%
Axon Enterprise Is Expanding Gross Margin
Growth companies frequently spend profits to expand their market share, but when a more mature company posts a loss, investors take note. Axon Enterprise (NASDAQ: AXON), founded in 1993, has been
5 Reasons to Be Bullish on Capital One
Credit card company Capital One Financial (NYSE: COF) has seen its stock price surge more than 63% year to date, and it's one of the top gainers in the financials sector. In the second quarter, the
1 Thing You Must Know Before Investing Any Money
Before you invest, the first question that probably comes to your mind is whether or not it's a good investment. Or maybe you wonder how much money you could make.
While these are great questions
1 Mistake Cannabis Investors Don't Want to Be Making Right Now
Federal marijuana legalization is getting more attention in the U.S., and it's now more about when, not if, the change will come to pass. Senate Majority Leader Chuck Schumer released a draft bill
Is Globus Medical's Robotic Surgery Business a Winner?
Medical device maker Globus Medical (NYSE: GMED) has been around since 2003, but has only been selling its Excelcius GPS surgery robots since 2017. Its legacy business is well established, but many
2 Supercharged Growth Stocks to Buy Right Now
The world is undeniably becoming more digital. And as things like advertising, commerce, and payments move to digital channels, investors have an opportunity to buy into these wealth-creating
Weber's IPO Is Next Week. Here's What Investors Need to Know.
Just in time for summer grilling season, Weber (NYSE: WEBR) is setting the stage for its initial public offering (IPO). In an updated regulatory filing with the Securities and Exchange Commission
What Does the Market See in Wells Fargo That It Doesn't See in Citigroup?
If you look at this year's biggest gains in the financial industry, Wells Fargo (NYSE: WFC) is near the top of the list, with its stock climbing roughly 50% year to date. Citigroup (NYSE: C)
Should You Buy Activision Blizzard Stock Ahead of Q2 Earnings?
Activision Blizzard (NASDAQ: ATVI) is scheduled to report second-quarter earnings on Tuesday, Aug. 3, after the market closes. After soaring in 2020, the company's shares have barely budged year to
What Does Moderna's Addition to the S&P 500 Mean for Investors?
Moderna (NASDAQ: MRNA) was recently added to the S&P 500 index. This was a big milestone for the vaccine maker after its breakout year in 2020. In this Motley Fool Live video, recorded on July 19
Social Security Isn't Running Out of Money, but Here's Why I'm Pretending It Is
There are many rumors out there about Social Security, and perhaps the most prominent one is that the program is on the verge of running out of money. In other words, so long future benefits, right?
Why Investors Should Think Twice Before Investing in ContextLogic -- or Wish
Maybe it is because ContextLogic (NASDAQ: WISH) is a global e-commerce company. Maybe it's because it's a newly public. Or maybe it's gotten caught up in the Reddit crowd. For whatever reason, a lot
Is This Mid-Cap Biotech Stock a Buy Now?
Kodiak Sciences (NASDAQ: KOD) is a mid-cap biotech business building a drug portfolio focused on retina therapeutics. The Palo Alto, California based company has an approximate market cap of $4.5


